The Global Regenerative Medicine Partnering
2010-2015: Deal trends, players, financials and forecasts report provides
comprehensive understanding and unprecedented access to the regenerative
medicine including cell therapy, organ regeneration, stem cells and tissue
regeneration partnering deals and agreements entered into by the worlds leading
healthcare companies.
Description
The Global Regenerative Medicine Partnering
2010-2015: Deal trends, players, financials and forecasts report provides
comprehensive understanding and unprecedented access to the regenerative
medicine including cell therapy, organ regeneration, stem cells and tissue
regeneration partnering deals and agreements entered into by the worlds leading
healthcare companies.
Trends in regenerative medicine
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and
stem cells
Track future trends and emerging companies in
regenerative medicine- *new feature*
The report takes readers through the regenerative
medicine deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are currently entering
regenerative medicine partnering deals.
The report presents average financial deal terms
values for regenerative medicine deals, where available listing by overall
headline values, upfront payments, milestones and royalties enabling readers to
analyse and benchmark the value of current deals.
The middle section of the report explores the
leaders in the regenerative medicine partnering field; both the leading deal
values and leading players are reported allowing readers to see who is
succeeding in this growing market. This chapter also looks at the contributions
by the big pharma and big biotech companies of the world in terms of deals
made.
One of the key highlights of the report is that
over 700 online deals records of actual regenerative medicine deals as
disclosed by the deal parties are included towards the end of the report in a
directory format that is easy to reference. Each deal links via Weblink to an
online version and all these deals are organized by company A-Z, stage of
development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), specific therapy and technology focus. In addition the report
includes actual contract documents where available as submitted to the
Securities Exchange Commission by companies and their deal partners.
For example,
analyzing actual company deals and agreements allows assessment of the
following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The initial chapters of the report provide an
orientation of regenerative medicine dealmaking and its associated business and
partnering activities. This chapter provides an overall introduction to the
report and what you will learn from it, whilst chapter 2 provides an overview
of the trends in regenerative medicine deal making since 2010, categorizing by
deal type, industry sector, stage of development and technology type.
A popular chapter with readers chapter 3 covers the
average financial deal terms for deals signed in the regenerative medicine
field with a stage of development announced. Deals are listed and sectioned by
average headlines, upfront payments, milestone payments and royalty rates. The
median values of these deals are then presented by stage of development at
signing.
Numerous tables and figures are weaved within the
report to support the findings and illustrate the trends and activities in
regenerative medicine partnering and dealmaking since 2010.
Chapter 4 covers the leading regenerative medicine
deals that have been announced over the past five years. Deals are listed by
headline value. Where the deal has an agreement contract published at the SEC a
link provides online access to the contract. Full deal contract documents where
available for each deal are indicated by a yes/no symbol. Within this chapter
the most active regenerative medicine deal makers are also listed as well as
the deal making activities and the number of deals entered into by the big
pharma and biotech companies.
Chapter 5 acts as a contracts reference directory
chapter providing a full comprehensive and detailed list of the regenerative
medicine partnering deals signed and announced since January 2010. This chapter
is organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc), and therapy focus. In
order for readers to view full details of each agreement the report is
formatted so that each deal title links via Weblink to an online version of the
actual deal at Current Agreements deals and alliances database.
Chapter 6 brings the report to a conclusion by
looking ahead to the future of regenerative medicine partnering. Newly
introduced to provide readers with potential prospects and partnering insights
this chapter selects emerging companies to watch in 2015 and details their
recent deal making and financial activities. These companies could be potential
targets for those who want to invest or partner in the coming months.
In conclusion, this report gives prospective
dealmakers a thorough overview of all the deals announced in the regenerative
medicine field preparing them with everything they need to know about
partnering in the research, development and commercialization of regenerative
medicine technologies and products.
A full appendix is provided at the very end of the
report which lists all the regenerative medicine deals announced since 2010
categorized by company A-Z, deal type, stage of development, technology and
therapy. Where available contract documents are supplied, these documents
include additional deal information in comparison to only the brief summary
that is provided through a press release. Readers can analyze the contracts
fully by reviewing the detailed terms between the parties under which monies
and licensing rights are exchanged. The appendix is useful for looking at all
the deals signed by one specific company.
Benefits
- Global Regenerative Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
- In-depth understanding of regenerative medicine and stem cells deal trends since 2010
- Includes cell therapy, organ regeneration, stem cells and tissue regeneration deals
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
- Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma - companies, together with real world clause examples
- Full listing of regenerative medicine and stem cells deals by company A-Z, deal value, deal type, and therapy focus
- Identify leading regenerative medicine and stem cells deals by value since 2010
- Identify the most active regenerative medicine and stem cells dealmakers since 2010
- Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
- Track future trends and emerging companies in the field of regenerative medicine
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 1092 pages, “Global
Regenerative Medicine Partnering 2010-2015: Deal trends, players, financials
and forecasts” report
covers the Executive Summary, Introduction, Trends in regenerative medicine
dealmaking, Average financial deal terms for regenerative medicine partnering,
Leading regenerative medicine deals, Regenerative medicine contracts directory,
Future trends and companies in regenerative medicine deal making, Appendices.
For
further information on this report, please visit-
http://mrr.cm/4Qo
Find all Diagnostics Reports
at: http://www.marketresearchreports.com/diagnostics
No comments:
Post a Comment
Note: only a member of this blog may post a comment.